Overview

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Status:
Completed

Trial end date:
2019-01-15

Target enrollment:

Participant gender:

Summary

The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.

Phase:

Phase 3

Details

Lead Sponsor:

Foamix Ltd.
Vyne Therapeutics Inc.